compani
creat bluematrix
mix competit intensifi head diabet
messag follow mix beat rais announc retir head
diabet manag market enriqu conterno surpris enter
period intensifi competit surpris see investor react
neg mr conterno departur follow leadership chang bio-medicin
christi shaw dr levi garraway ep beat estim
boost tax rate bp us sale beat us
miss consensu growth asset trulic taltz emgal miss
est opm forecast bp reiter neutral
rate
detail oper margin miss estim lower tax boost
ep report ep beat estim street
sale million y/i street million differ
estim million differ sale upsid vs
estim driven sale grew million howev
key product trulic type diabet product taltz psoriasi emgal
cgrp migrain estim like due competit mix increas
exposur donut hole/reb quarter estim gross net
trulic monthli price sequenti
gross margin consensu forecast
cite unfavor product mix primarili reflect loss patent exclus
ciali impact lower realiz price sg
aggreg modest headwind increas bp y/i sale primarili due
 invest late-stag pipelin asset oper margin decreas bp y/i
well forecast rais question compani oper
margin target come surpris wake manag high
convict commentari result support target oper incom
million estim million consensu
million unusu low tax rate bp estim
main driver ep upsid vs forecast
ep guidanc rais lower tax rate boost result ep
guidanc rais larg driven anticip
tax benefit maintain revenu guidanc billion gross
margin guidanc maintain non-gaap basi oper incom
expens guidanc tighten million previou rang
million tax rate guidanc lower
guidanc sg billion billion unchang
obviou catalyst ahead next month stock-mov pipelin
catalyst remain see note global pharma preview jardianc
emperor-hfref emperor-hfpef key data readout azn farxiga
shown posit result hfref popul dapa-hf result see note practice-
chang data azn farxiga hfref remain cautiou phase data lung
cancer data compani asset expect acknowledg
alreadi low expect asset wake fail pancreat cancer studi
earn confer call detail morn wednesday octob
edt dial passcod webcast link
page analyst certif import disclosur
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
compani next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori compani
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
